147 related articles for article (PubMed ID: 2257308)
1. Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice.
Porter JB; Morgan J; Hoyes KP; Burke LC; Huehns ER; Hider RC
Blood; 1990 Dec; 76(11):2389-96. PubMed ID: 2257308
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice.
Porter JB; Hoyes KP; Abeysinghe RD; Brooks PN; Huehns ER; Hider RC
Blood; 1991 Nov; 78(10):2727-34. PubMed ID: 1824264
[TBL] [Abstract][Full Text] [Related]
3. In vivo evaluation of hydroxypyridone iron chelators in a mouse model.
Gyparaki M; Porter JB; Hirani S; Streater M; Hider RC; Huehns ER
Acta Haematol; 1987; 78(2-3):217-21. PubMed ID: 3120475
[TBL] [Abstract][Full Text] [Related]
4. Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload.
Kontoghiorghes GJ; Barr J; Nortey P; Sheppard L
Am J Hematol; 1993 Apr; 42(4):340-9. PubMed ID: 8493983
[TBL] [Abstract][Full Text] [Related]
5. Dose response studies using desferrioxamine and orally active chelators in a mouse model.
Kontoghiorghes GJ
Scand J Haematol; 1986 Jul; 37(1):63-70. PubMed ID: 3764334
[TBL] [Abstract][Full Text] [Related]
6. Protoporphyria induced by the orally active iron chelator 1,2-diethyl-3-hydroxypyridin-4-one in C57BL/10ScSn mice.
Smith AG; Clothier B; Francis JE; Gibbs AH; De Matteis F; Hider RC
Blood; 1997 Feb; 89(3):1045-51. PubMed ID: 9028337
[TBL] [Abstract][Full Text] [Related]
7. Selection of hydroxypyridin-4-ones for the treatment of iron overload using in vitro and in vivo models.
Huehns ER; Porter JB; Hider RC
Hemoglobin; 1988; 12(5-6):593-600. PubMed ID: 3209401
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94.
Chenoufi N; Hubert N; Loréal O; Morel I; Pasdeloup N; Cillard J; Brissot P; Lescoat G
J Hepatol; 1995 Aug; 23(2):166-73. PubMed ID: 7499788
[TBL] [Abstract][Full Text] [Related]
9. Short-term oral 3-hydroxypyridin-4-one dosing increases aluminum excretion and partially reverses aluminum-induced toxicity in the rabbit independent of chelator lipophilicity.
Yokel RA; Meurer KA; Hong CB; Dickey KM; Skinner TL; Fredenburg AM
Drug Metab Dispos; 1997 Feb; 25(2):182-90. PubMed ID: 9029049
[TBL] [Abstract][Full Text] [Related]
10. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts.
Selig RA; White L; Gramacho C; Sterling-Levis K; Fraser IW; Naidoo D
Cancer Res; 1998 Feb; 58(3):473-8. PubMed ID: 9458092
[TBL] [Abstract][Full Text] [Related]
11. PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice.
Wong CS; Kwok JC; Richardson DR
Biochim Biophys Acta; 2004 Dec; 1739(1):70-80. PubMed ID: 15607119
[TBL] [Abstract][Full Text] [Related]
12. Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyridin-4-one, CP94, relates to differing metabolism of the iron chelating site.
Porter JB; Abeysinghe RD; Hoyes KP; Barra C; Huehns ER; Brooks PN; Blackwell MP; Araneta M; Brittenham G; Singh S
Br J Haematol; 1993 Sep; 85(1):159-68. PubMed ID: 8251385
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of 2-amido-3-hydroxypyridin-4(1H)-ones: novel iron chelators with enhanced pFe3+ values.
Liu ZD; Piyamongkol S; Liu DY; Khodr HH; Lu SL; Hider RC
Bioorg Med Chem; 2001 Mar; 9(3):563-73. PubMed ID: 11310590
[TBL] [Abstract][Full Text] [Related]
14. The effect of N-alkyl modification on the antimalarial activity of 3-hydroxypyridin-4-one oral iron chelators.
Hershko C; Theanacho EN; Spira DT; Peter HH; Dobbin P; Hider RC
Blood; 1991 Feb; 77(3):637-43. PubMed ID: 1991172
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis.
Hoyes KP; Jones HM; Abeysinghe RD; Hider RC; Porter JB
Exp Hematol; 1993 Jan; 21(1):86-92. PubMed ID: 8417963
[TBL] [Abstract][Full Text] [Related]
16. Iron chelators as therapeutic agents against Pneumocystis carinii.
Weinberg GA
Antimicrob Agents Chemother; 1994 May; 38(5):997-1003. PubMed ID: 8067783
[TBL] [Abstract][Full Text] [Related]
17. Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds.
Porter JB; Singh S; Hoyes KP; Epemolu O; Abeysinghe RD; Hider RC
Adv Exp Med Biol; 1994; 356():361-70. PubMed ID: 7887242
[No Abstract] [Full Text] [Related]
18. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools.
Hoyes KP; Porter JB
Br J Haematol; 1993 Oct; 85(2):393-400. PubMed ID: 8280612
[TBL] [Abstract][Full Text] [Related]
19. Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig.
Wong A; Alder V; Robertson D; Papadimitriou J; Maserei J; Berdoukas V; Kontoghiorghes G; Taylor E; Baker E
Biometals; 1997 Oct; 10(4):247-56. PubMed ID: 9353871
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans.
Thuma PE; Olivieri NF; Mabeza GF; Biemba G; Parry D; Zulu S; Fassos FF; McClelland RA; Koren G; Brittenham GM; Gordeuk VR
Am J Trop Med Hyg; 1998 Mar; 58(3):358-64. PubMed ID: 9546419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
